Home › Research › Biomarkers
Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China
Zi-yi Wang, Jia-Wei Xin, Mingyu Wang, Shufen Chen, Keliang Chen, Jiaying Lu, Y Huang, Wei Zhang et al.. Neurology, 2026-06-18
Topic: Amyloid, tau and blood-test diagnosis
= 0.007) in AD-signature regions and a numerically higher burden of vascular risk factors. In a large cohort from a specialized tertiary memory clinic, clinical-biological stage discordance under the 2024 AD criteria was common among amyloid-positive individuals. Distinct cognitive, educational, biomarker, and neuroanatomic profiles characterized susceptible, typical, and resilient subgroups. In addition, plasma p-tau217 showed a stepwise increase across tau PET stages, supporting its utility as a blood-based marker of tau pathology severity. These findings support the clinical relevance of the revised staging framework and may inform future refinements of AD diagnostic guidelines. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the 2024 revised biological and clinical criteria for AD demonstrate clinical utility in a Chinese cohort from a specialized tertiary memory clinic.
Key findings
- = 0.007) in AD-signature regions and a numerically higher burden of vascular risk factors.
- In a large cohort from a specialized tertiary memory clinic, clinical-biological stage discordance under the 2024 AD criteria was common among amyloid-positive individuals.
- Distinct cognitive, educational, biomarker, and neuroanatomic profiles characterized susceptible, typical, and resilient subgroups.
- In addition, plasma p-tau217 showed a stepwise increase across tau PET stages, supporting its utility as a blood-based marker of tau pathology severity.
- These findings support the clinical relevance of the revised staging framework and may inform future refinements of AD diagnostic guidelines.
Why it matters
In a Chinese memory clinic cohort, clinical and biological staging under the 2024 criteria often disagreed among amyloid-positive individuals, and plasma p-tau217 rose stepwise across tau PET stages. These findings support the clinical relevance of the revised staging framework for diagnosis, not a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants1,214
- Evidence strengthModerate
How this study scored 49/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,214 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jin‐Tai Yu: h-index 94 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Fudan University: institution h-index 954 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42314105) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Wang, Z.-y., Xin, J.-W., Wang, M., Chen, S., Chen, K., Lu, J., et al. (2026). Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China. Neurology. https://doi.org/10.1212/wnl.0000000000218184
Vancouver
Wang Z.-y, Xin J.-W, Wang M, Chen S, Chen K, Lu J, et al. Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China. Neurology. 2026. doi:10.1212/wnl.0000000000218184. PMID: 42314105.
BibTeX
@article{wang2026-42314105,
author = {Wang, Zi-yi and Xin, Jia-Wei and Wang, Mingyu and Chen, Shufen and Chen, Keliang and Lu, Jiaying and Huang, Y and Zhang, Wei and others},
title = {{Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China}},
journal = {Neurology},
year = {2026},
doi = {10.1212/wnl.0000000000218184},
pmid = {42314105},
url = {https://doi.org/10.1212/wnl.0000000000218184}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.